Instem has delivered a strong set of FY15 prelims, in line to slightly ahead of expectations. Strong organic revenue growth of 22% translated into a 49% increase in operating profits, driven by increased activity across the group. The outlook remains very positive, particularly around the FDA’s SEND initiative, but also supported by buoyant conditions generally in the early drug development market. Recent contract wins leave our forecasts looking increasingly well underpinned, with further poten ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong FY15, expecting more in FY16
- Published:
05 Apr 2016 -
Author:
Chris Glasper -
Pages:
7
Instem has delivered a strong set of FY15 prelims, in line to slightly ahead of expectations. Strong organic revenue growth of 22% translated into a 49% increase in operating profits, driven by increased activity across the group. The outlook remains very positive, particularly around the FDA’s SEND initiative, but also supported by buoyant conditions generally in the early drug development market. Recent contract wins leave our forecasts looking increasingly well underpinned, with further poten ....